AIDS 2010
AIDS 2010: Once-daily Extended Release Nevirapine (Viramune) Equals Twice-daily Immediate Release Formulation
- Details
- Category: HIV Treatment
- Published on Friday, 27 August 2010 13:56
- Written by Liz Highleyman
A once-daily extended-release formulation of nevirapine (Viramune) suppresses HIV viral load as well as the older immediate-release pill, and may cause fewer or milder side effects, according to a late-breaker presentation at the XVIII International AIDS Conference (AIDS 2010) last week in Vienna. The more convenient once-daily formulation is likely to be especially beneficial in resource-limited countries where the drug is still widely used.
AIDS 2010: HPV-associated Cancer among HIV Positive Men and Women in the Combination ART Era
- Details
- Category: Human Papillomavirus (HPV)
- Published on Tuesday, 24 August 2010 13:56
- Written by Liz Highleyman
Precancerous anal cell changes and infection with high-risk human papillomavirus (HPV) types remain common among men with HIV despite effective antiretroviral therapy (ART) that suppresses viral load and restores CD4 cell levels, according to a study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. A related study found that invasive cervical cancer -- also caused by HPV -- was associated with lower CD4 cell counts among HIV positive women in the large NA-ACCORD cohort.
Long-term Non-progression of HIV Disease without Antiretroviral Treatment Is Uncommon
- Details
- Category: HIV Disease Progression
- Published on Friday, 20 August 2010 13:56
- Written by Liz Highleyman
Less than 1% of people infected with HIV for 15 years did not experience disease progression in the absence of antiretroviral therapy (ART), according to findings from the CASCADE cohort reported at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna. Even at 5 years after seroconversion, all but 10% progressed to the point of requiring treatment, and only 0.25% were considered HIV controllers with sustained undetectable viral load.
AIDS 2010: HIV Treatment Advances Have Not Decreased Mortality among Disadvantaged Groups in San Francisco
- Details
- Category: HIV Treatment
- Published on Tuesday, 24 August 2010 13:56
- Written by Liz Highleyman
While effective combination antiretroviral therapy (ART) has reduced overall morbidity and mortality due to HIV/AIDS, everyone has not benefited equally. According to a San Francisco study presented at the XVIII International AIDS Conference (AIDS 2010) last month in Vienna, members of socially disadvantaged groups -- including injection drug users, heavy alcohol users, individuals with mental health problems, people of color, women, and transgender people -- were less likely to achieve undetectable HIV viral load and their all-cause mortality increased slightly rather than falling over time.
Switching from Efavirenz to Etravirine Reduces Central Nervous System Side Effects
- Details
- Category: HIV Treatment
- Published on Friday, 20 August 2010 13:56
- Written by Liz Highleyman
HIV patients who started antiretroviral treatment using the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (Intelence) experienced fewer neuropsychiatric side effects such as abnormal dreams and anxiety compared with those taking efavirenz (Sustiva), and those who switched from efavirenz to etravirine saw an improvement in such symptoms, according to 2 studies presented last month at the XVIII International AIDS Conference (AIDS 2010) in Vienna.
More Articles...
- AIDS 2010: Boosted Darunavir (Prezista) Monotherapy Provides Durable Viral Suppression for Most HIV Patients
- AIDS 2010: Nutritional Supplements May Slow HIV Disease Progression, Boost Immune Recovery, and Lessen Mitochondrial Toxicity
- AIDS 2010: Drug Resistance Linked to Faster Hepatitis B Liver Disease Progression in HIV/HBV Coinfected Patients
- AIDS 2010: HIV/HCV Coinfected People with Normal Liver Enzymes Respond Well to Interferon-based Therapy
Web Design and Development by